We describe recovery of vision and postreceptor retinal function but not photoreceptor function following severe, acute visual impairment associated with high-dose desferoxamine (DFO) used to chelate iron in a 36-year-old woman with β-thalassemia major.1,2 Survival of patients with β-thalassemia necessitates long-term transfusion with consequent iron overload of vital organs, for which chelation therapy is mandatory.